Assi Chahine, Samaha Camille, Chamoun Moussa Moussa, Hayek Tony, Yammine Kaissar
Department of Orthopedic Surgery, Lebanese American Hospital Medical Center-Rizk Hospital, Beirut, Lebanon (CA, CS, TH, KY), Center for Evidence-based Anatomy, Sports and Orthopedic Research, Beirut, Lebanon.
Hopital Libano-Francais, Zahle, Lebanon (MC), Center for Evidence-based Anatomy, Sports and Orthopedic Research, Beirut, Lebanon.
Foot Ankle Spec. 2019 Oct;12(5):432-438. doi: 10.1177/1938640018816378. Epub 2018 Dec 7.
. Soft tissue defects in the distal leg and foot are challenging conditions for reconstruction. The widely used reverse sural fascio-cutaneous flap (RSFCF) has been reported with large variation in complication frequency. Some authors reported higher complications in the diabetic population when compared with trauma patients. We compared the reliability of the RSFCF in treating such defects among both populations. . This is a retrospective series with a prospective data collection of 24 patients (11 with type 2 diabetes and 13 in trauma settings) treated with an ipsilateral RSFCF for soft tissue defects of the distal leg and the rear foot. Healing events and complications were recorded and compared for both groups. The mean follow-up was 32 months. . Diabetic group versus trauma group showed the following results; mean flap healing time of 24 versus 22 days, donor site healing time of 14 versus 16 days, 1 total flap necrosis in both groups, 3 versus 2 cases of skin edge necrosis, 2 cases of temporary venous congestion in both groups, and 8 versus 10 cases of transient hypoesthesia of the lateral border of the foot. No infection was encountered in both groups and no recurrence of infection in the primary infected diabetic patients. . We found the RSFCF to be useful, reproducible, and reliable in treating soft tissue defects with a very low frequency of serious complications. Diabetic patients were found to have similar outcomes when compared with trauma patients. Therefore, diabetes might not be a major factor of flap failure. Level III: Therapeutic.
小腿远端和足部的软组织缺损是重建手术中具有挑战性的情况。据报道,广泛使用的逆行腓肠筋膜皮瓣(RSFCF)并发症发生率差异很大。一些作者报告称,与创伤患者相比,糖尿病患者的并发症发生率更高。我们比较了RSFCF在这两类人群中治疗此类缺损的可靠性。
这是一项回顾性系列研究,前瞻性收集了24例患者的数据(11例2型糖尿病患者和13例创伤患者),这些患者均接受同侧RSFCF修复小腿远端和后足的软组织缺损。记录并比较两组的愈合情况和并发症。平均随访时间为32个月。
皮瓣平均愈合时间分别为24天和22天,供区愈合时间分别为14天和16天,两组均有1例皮瓣完全坏死,皮肤边缘坏死分别为3例和2例,两组均有2例出现暂时性静脉淤血,足部外侧缘短暂感觉减退分别为8例和10例。两组均未发生感染,原发性感染的糖尿病患者也未出现感染复发。
我们发现RSFCF在治疗软组织缺损方面是有用、可重复且可靠的,严重并发症发生率极低。与创伤患者相比,糖尿病患者的预后相似。因此,糖尿病可能不是皮瓣失败的主要因素。III级:治疗性研究。